by Elena Iemma | Jan 12, 2026 | Blog
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Mar 5, 2024 | Events
June 13 & 14, 2024 9:00am – 5:00pm (with receptions to follow!) 350 Eddy St. Providence, RI 02903 Registration is closed The Artificial Intelligence / Human Intelligence & Immunoinformatics Workshop will take place on June 13 and 14th at the South Street...
by Elena Iemma | Sep 10, 2021 | Events
EpiVax participated in the 2021 International Society for Vaccines (ISV) Annual Virtual Congress September 13-15, 2021. The 2021 Congress was a busy one, it’s been a difficult but innovative period for the vaccine development community. Multiple EpiVax...
by Elena Iemma | Jul 6, 2021 | News
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...
by Elena Iemma | May 13, 2021 | News
PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method...
